Pharma Journalist -

Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, launched following the closing…
Read More...

Visus Therapeutics Inc., a clinical stage biopharmaceutical company focused on developing multi-targeted treatments for the eye, announced it has expanded its pipeline via the…
Read More...

Arsenal Biosciences, Inc. (ArsenalBio), a privately held programmable cell therapy company engineering advanced CAR T therapies for solid tumors, announced a multi-year collaboration…
Read More...

Koselugo (selumetinib) has been approved in Japan for the treatment of paediatric patients three years of age and older with plexiform neurofibromas (PNs) in neurofibromatosis type 1…
Read More...

Merck known as MSD outside of the United States and Canada, announced that KEYTRUDA, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and…
Read More...

Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design platform for genetic medicine, announced a strategic collaboration with Sanofi for the use of…
Read More...

Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease and SynerK, a leading RNAi…
Read More...

Atamyo Therapeutics, a biotechnology company focused on the development of new-generation gene therapies targeting neuromuscular diseases, announced the dosing with ATA-100 of a first…
Read More...

Pulse Biosciences, Inc. a novel bioelectric medicine company developing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, announced receipt of U.S. Food and Drug…
Read More...

Pfizer Inc. and BioNTech SE announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster…
Read More...